Khiron Life Sciences Corp. (Khiron or the Company) announced the appointment of Chris Naprawa as Director and Chairman of the Board. In transitioning from his current role as President, Chris will continue to guide the Company and Board as Khiron continues its commercialization phase of its medical cannabis business strategy in Latin America and globally. The Company further announced that Michael Beck has resigned from the Board, including as member of the Audit and Compensation Committees, effective immediately.